434 related articles for article (PubMed ID: 8521382)
1. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression.
Geradts J; Kratzke RA; Niehans GA; Lincoln CE
Cancer Res; 1995 Dec; 55(24):6006-11. PubMed ID: 8521382
[TBL] [Abstract][Full Text] [Related]
2. Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines.
Sartor M; Steingrimsdottir H; Elamin F; Gäken J; Warnakulasuriya S; Partridge M; Thakker N; Johnson NW; Tavassoli M
Br J Cancer; 1999 Apr; 80(1-2):79-86. PubMed ID: 10389982
[TBL] [Abstract][Full Text] [Related]
3. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers.
Geradts J; Fong KM; Zimmerman PV; Maynard R; Minna JD
Clin Cancer Res; 1999 Apr; 5(4):791-800. PubMed ID: 10213214
[TBL] [Abstract][Full Text] [Related]
4. Increased p16 levels correlate with pRb alterations in human urothelial cells.
Yeager T; Stadler W; Belair C; Puthenveettil J; Olopade O; Reznikoff C
Cancer Res; 1995 Feb; 55(3):493-7. PubMed ID: 7834615
[TBL] [Abstract][Full Text] [Related]
5. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.
Ueki K; Ono Y; Henson JW; Efird JT; von Deimling A; Louis DN
Cancer Res; 1996 Jan; 56(1):150-3. PubMed ID: 8548755
[TBL] [Abstract][Full Text] [Related]
6. Abnormal expression of cell cycle regulatory proteins in ductal and lobular carcinomas of the breast.
Geradts J; Ingram CD
Mod Pathol; 2000 Sep; 13(9):945-53. PubMed ID: 11007034
[TBL] [Abstract][Full Text] [Related]
7. Altered p16INK4 and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity.
Kinoshita I; Dosaka-Akita H; Mishina T; Akie K; Nishi M; Hiroumi H; Hommura F; Kawakami Y
Cancer Res; 1996 Dec; 56(24):5557-62. PubMed ID: 8971152
[TBL] [Abstract][Full Text] [Related]
8. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.
Huang L; Goodrow TL; Zhang SY; Klein-Szanto AJ; Chang H; Ruggeri BA
Cancer Res; 1996 Mar; 56(5):1137-41. PubMed ID: 8640773
[TBL] [Abstract][Full Text] [Related]
9. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.
Gonzalez-Zulueta M; Bender CM; Yang AS; Nguyen T; Beart RW; Van Tornout JM; Jones PA
Cancer Res; 1995 Oct; 55(20):4531-5. PubMed ID: 7553622
[TBL] [Abstract][Full Text] [Related]
10. Infrequent alternations of RB pathway (Rb-p16INK4A-cyclinD1) in adenoid cystic carcinoma of salivary glands.
Shintani S; Mihara M; Nakahara Y; Kiyota A; Yoshihama Y; Ueyama Y; Matsumura T
Anticancer Res; 2000; 20(3B):2169-75. PubMed ID: 10928172
[TBL] [Abstract][Full Text] [Related]
11. Cyclin D1 amplification is independent of p16 inactivation in head and neck squamous cell carcinoma.
Okami K; Reed AL; Cairns P; Koch WM; Westra WH; Wehage S; Jen J; Sidransky D
Oncogene; 1999 Jun; 18(23):3541-5. PubMed ID: 10376532
[TBL] [Abstract][Full Text] [Related]
12. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
Elisei R; Shiohara M; Koeffler HP; Fagin JA
Cancer; 1998 Nov; 83(10):2185-93. PubMed ID: 9827724
[TBL] [Abstract][Full Text] [Related]
13. Aberrant expression of cell-cycle regulatory proteins in human mesenchymal neoplasia.
Creager AJ; Cohen JA; Geradts J
Cancer Detect Prev; 2001; 25(2):123-31. PubMed ID: 11341347
[TBL] [Abstract][Full Text] [Related]
14. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.
Schutte M; Hruban RH; Geradts J; Maynard R; Hilgers W; Rabindran SK; Moskaluk CA; Hahn SA; Schwarte-Waldhoff I; Schmiegel W; Baylin SB; Kern SE; Herman JG
Cancer Res; 1997 Aug; 57(15):3126-30. PubMed ID: 9242437
[TBL] [Abstract][Full Text] [Related]
15. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression.
Reed JA; Loganzo F; Shea CR; Walker GJ; Flores JF; Glendening JM; Bogdany JK; Shiel MJ; Haluska FG; Fountain JW
Cancer Res; 1995 Jul; 55(13):2713-8. PubMed ID: 7796391
[TBL] [Abstract][Full Text] [Related]
16. p16/pRb pathway alterations are required for bypassing senescence in human prostate epithelial cells.
Jarrard DF; Sarkar S; Shi Y; Yeager TR; Magrane G; Kinoshita H; Nassif N; Meisner L; Newton MA; Waldman FM; Reznikoff CA
Cancer Res; 1999 Jun; 59(12):2957-64. PubMed ID: 10383161
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of key cell cycle genes (p16/cyclin D1/pRb) in head and neck squamous carcinomas.
Lai S; El-Naggar AK
Lab Invest; 1999 Mar; 79(3):255-60. PubMed ID: 10092061
[TBL] [Abstract][Full Text] [Related]
18. Rb and p16INK4a expression in resected non-small cell lung tumors.
Kratzke RA; Greatens TM; Rubins JB; Maddaus MA; Niewoehner DE; Niehans GA; Geradts J
Cancer Res; 1996 Aug; 56(15):3415-20. PubMed ID: 8758904
[TBL] [Abstract][Full Text] [Related]
19. Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma.
Dreyling MH; Bullinger L; Ott G; Stilgenbauer S; Müller-Hermelink HK; Bentz M; Hiddemann W; Döhner H
Cancer Res; 1997 Oct; 57(20):4608-14. PubMed ID: 9377576
[TBL] [Abstract][Full Text] [Related]
20. Lack of mutation in the cyclin-dependent kinase inhibitor, p19INK4d, in tumor-derived cell lines and primary tumors.
Zariwala M; Xiong Y
Oncogene; 1996 Nov; 13(9):2033-8. PubMed ID: 8934552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
